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ZebraﬁshA novel microdeletion of 14q13.1q13.3 was identiﬁed in a patient with developmental delay and intractable
epilepsy. The 2.2-Mb deletion included 15 genes, of which TULIP1 (approved gene symbol: RALGAPA1)was
the only gene highly expressed in the brain. Western blotting revealed reduced amount of TULIP1 in cell
lysates derived from immortalized lymphocytes of the patient, suggesting the association between TULIP1
haploinsufﬁciency and the patient's phenotype, then 140 patients were screened for TULIP1 mutations and
four missense mutations were identiﬁed. Although all four missense mutations were common with parents,
reduced TULIP1 was observed in the cell lysates with a P297T mutation identiﬁed in a conserved region
among species. A full-length homolog of human TULIP1 was identiﬁed in zebraﬁsh with 72% identity to
human. Tulip1 was highly expressed in zebraﬁsh brain, and knockdown of which resulted in brain
developmental delay. Therefore, we suggest that TULIP1 is a candidate gene for developmental delay.
Crown Copyright © 2009 Published by Elsevier Inc. All rights reserved.Submicroscopic chromosomal aberrations are considered to com-
prise up to 15% of all mutations underlying monogenic diseases [1].
Microarray-based comparative genomic hybridization (aCGH) has
accelerated to identify such submicroscopic genomic alterations, and
many new microdeletion syndromes have been established [2].
Whereas interstitial deletion of 14q13 is rare and only a few patients
have been reported. By use of aCGH analyses, we identiﬁed a unique
14q13.1q13.3microdeletion in a patient with developmental delay and
intractable epilepsy. Of the 15 genes identiﬁed in the microdeletion
region, TULIP1 (approved gene symbol: RALGAPA1)was the only one
known to be predominantly expressed in normal brain tissue [3]. To
evaluate the contribution of TULIP1 to the patient's neurological
symptoms, zebraﬁsh embryos with morpholino knockdown system
was used as a model organism [4]. Our results suggest that TULIP1 is a
candidate gene for developmental delay and epilepsy.amoto).
09 Published by Elsevier Inc. All riResults
Molecular cytogenetic analyses of 14q13.1q13.3 deletion
For patient 1 (P1), a 2.2-Mb microdeletion of 14q13.1q13.3
(33,462,439//35,694,522) was identiﬁed using aCGH (Fig. 1). Two-
color ﬂuorescent in situ hybridization (FISH) analysis conﬁrmed the
deletion of 14q13.1q13.3 by the loss of the RP11-26M6 and RP11-
35M15 signals (Fig. 2A). Retrospective evaluation of chromosomal G-
banding previously provided normal karyotype showed reasonable
ﬁnding with loss of white band (Fig. 2B). FISH analysis using the same
probes revealed that bothparents lacked the deletion (data not shown),
which indicated de novo deletion in P1. The ﬁnal karyotypewas arr cgh
14q13.1q13.3(33,462,439-35,694,522) ×1.ish(RP11-557O15+,RP11-
26M6−,RP11-35M15−,RP11-81F13+,RP11-112H5+) de novo.
To conﬁrm the biological parent–child relationships, microsatellite
marker analysis was performed on P1 family members. The results
sufﬁciently veriﬁed the biological relationships in this family
(Supplementary Table 1) and revealed that P1 had only one peak of
D14S70, which is within the deletion region; this peak was common
only with the mother and there was no common peak of D14S70 withghts reserved.
Fig. 1. The result of aCGH showing chromosomal deletion of 14q13.1q13.3 on Chromosome View (upper) and Gene View (bottom). Blue rectangles indicate the region of genomic
copy number aberrations. In Gene View, the deletion region was expanded. Axial dimension indicates the physical location on chromosome 14, and vertical dimension indicates log2
ratio of intensity. Spots indicate the location of probes. Black bars indicate the locations of the known genes. Red and green bars indicate the locations of BAC clones used for FISH
analyses. Italic characters indicate gene symbols.
415K. Shimojima et al. / Genomics 94 (2009) 414–422the father (Fig. 2C). These data indicated that the paternally derived
allele at this locus was deleted in P1.
Detailed clinical phenotype of P1
At the time of the study, P1 was a 7-year-old girl. Her birth weight
was 3038 g and her head circumference at birthwas 36 cm; therewereFig. 2. Molecular cytogenetic analysis of the deletion of 14q13.1q13.3 in P1. (A) FISH anal
indicated the deletion by the loss of green signal. (B) G-banded chromosome 14 of P1 exhibite
data indicated that the D14S70 band was only common to P1 and her mother (see also Supno documented neonatal events. At 2 months, she suffered a seizure
that continued for a couple ofminutes; at that time she openedher eyes
andboth eyes and armsmovedupward andwereﬁxed. Because similar
seizures occurred three times during the next 2 h, shewas hospitalized.
Brain computed tomography (CT) scan and electroencephalography
(EEG) revealed no abnormalities. Seizures were refractory to epilepsy
medication and occurred a couple of times per day. Similar to Westysis using RP11-112H5 (SpectrumOrange) and RP11-35M15 (SpectrumGreen) probes
d deletion of thewhite band (arrow). (C) GeneMapper analysis of microsatellite marker
plementary Table 1).
Fig. 3. Western blot analysis of TULIP1 expression. Cell lysates from immortalized
lymphocytes derived from the patients indicated at the top were analyzed by Western
blotting using a rabbit anti-GARNL1 (TULIP1) polyclonal antibody. P1 and P2 exhibited
reduced TULIP1 expression (upper panel). β-Actin levels were evaluated as a control
(lower panel).
416 K. Shimojima et al. / Genomics 94 (2009) 414–422syndrome, her seizures were composed of a series of attacks and
occurred once a week after the patient reached 3 months of age.
When she was 9 months old, P1 was referred to our institution for
treatment of the intractable seizures. There were no dysmorphic
features. At that time, she was alert but her reaction to her
surroundings was poor. Her eyes could not follow a moving target.
Hypotonia was obvious but muscle power was enough to move
against gravity. There was no symptom of cranial nerve damage. Tonic
convulsions with eye movements and upward movement of the arms
were observed intermittently. Blood screening tests, including those
for inborn error of metabolism, revealed no abnormalities. The EEG
showed a diffuse θ wave and a high voltage θ burst during brief tonic
seizures (Supplementary Fig. 1A). However, there were no paroxys-
mal ﬁndings in intermittent phases. Brain magnetic resonance
imaging (MRI) showed mild brain atrophy (Supplementary Fig. 1B
and C). Brain single photon emission computed tomography (SPECT)
showed no areas of hypoperfusion (data not shown). The results from
other electrophysiological examinations, including auditory brain
response (ABR), visual evoked potential (VEP), somato-sensory
evoked potential (SSEP), conduction velocity (MCV), and sensory
verve conduction velocity (SCV), were within normal limits (data not
shown). Conventional chromosomal examination at 9 months of age
indicated a normal female karyotype with 46,XX. At 5 years of age, her
developmental level was evaluated using the Enjoji Scale of Infant
Analytical Development (ESID) and her developmental quotient was
determined to be 32 [5].
TULIP1 screening of additional patients with neurological disorders
Information regarding the genes within the deletion region of P1
was accumulated from the UCSC genome browser (http://www.
genome.ucsc.edu/); 15 genes were identiﬁed in the 2.8-Mb deleted
region (Fig. 1). Among the 15 genes, TULIP1was the only gene known
tobepredominantly expressed in thebrain. Thus,TULIP1wasexamined
as the candidate gene responsible for the clinical symptoms of P1.
Sequence analysis of the entire coding region of TULIP1, which
contains 41 exons, was performed using originally accumulated
40 patients' samples and the 100 research resource samples. Four
individual missense mutations were identiﬁed (Supplementary
Fig. 2). Patient 2 (P2) had a c.889CNA nucleotide alteration in exon
9, which is predicted to result in a P297T amino acid substitution. This
proband's father had the same alteration. Patient 3 (P3) and his father
had a c.1055ANG (D352G)mutation in exon 10. Patient 4 (P4) and her
mother had a c.1531GNA (A511T) mutation in exon 12. Patient 5 (P5)
and his father had a c.3132TNG (F914C) mutation. Thus, all of the four
missense mutations were inherited from healthy parents. Each of the
identiﬁed missense mutations was negative in 200 normal controls.
The entire coding region of TULIP1 remaining allele of P1 was
sequenced and was wild type.
P2 presented with severe mental retardation and intractable
epilepsy derived from bilateral perisylvian polymicrogyria. P4
suffered West syndrome in infancy, and manifested intractable
epilepsy and moderate mental retardation. P3 and P5 showed
moderate mental retardation, but no epilepsy (their family trees are
shown in Supplementary Fig. 3).
Analysis of TULIP1 expression
Western blotting using polyclonal rabbit anti-TULIP1 antibodywas
performed and reduced TULIP1 levels were conﬁrmed in immortal-
ized lymphocytes lysates from P1 and P2 (Fig. 3).
Identiﬁcation of zebraﬁsh tulip1
In zebraﬁsh, a homolog of human TULIP1was previously predicted
according to genomic information, but the gene has not yet beenisolated. Therefore, we cloned and sequenced the cDNA encoding
tulip1 from zebraﬁsh. Using RT-PCR, we identiﬁed two splice variants
of tulip1, tulip1.1 and tulip1.2, which sequences were deposited into
GenBank (accession AB476643 and AB476644). The shorter variant
(tulip1.1) consisted of 6201-bp and encoded a 2066-residue protein,
and the longer variant (tulip1.2) was 6318-bp and encoded a 2105
residue protein. Information from the zebraﬁsh genomic map
revealed that zebraﬁsh tulip1 was on chromosome 17 and consisted
of 41 exons. In addition, two splicing variants were identiﬁed based on
alternate usage of exon 40. Although the tulip1.2 variant lacks exon
40, this variant is longer than tulip1.1 because exon 40 contains a stop
codon. This exon–intron structure and alternative splicing of exon 40
are common to human and mouse TULIP1 [3], suggesting that tulip1 is
conserved through vertebrate evolution.
The deduced zebraﬁsh Tulip1.1 and Tulip1.2 protein sequences
exhibited 72% identity to the corresponding splicing variants from
both human and mouse, and the zebraﬁsh splice variants each
contained a Rap/Ran-GAP domain (aa 1848–aa 2027), two putative
transmembrane domains (aa 1184–aa1206, aa 1370–aa1392), two
putative coiled-coil motifs (aa 10–aa 37, aa 1738–aa 1770) and one
leucine zipper motif (aa 1074–aa 1088), all of which are also found in
human and mouse TULIP1 proteins at the same positions [3].
Collectively, these results suggested that zebraﬁsh tulip1.1 and tu-
lip1.2 are structural and functional homologs of human TULIP1.
To carry out tulip1 knockdown in zebraﬁsh using morpholino
antisense oligos, precise 5′ UTR nucleotide sequence information was
needed. Thus, we performed 5′ RACE to determine the sequence of the
tulip1 5′ UTR in our zebraﬁsh strain. Based on the obtained sequence
of a 64-nucleotide fragment immediately upstream of the transla-
tional initiation site, the residue at the 5′ terminus of this sequence
was guanine, whereas the residue of the position in the genomic
database was cytosine. This nucleotide alteration was supposed to be
the result of m7G 5′ cap structure. Therefore, this fragment means to
be a full length of the 5′ UTR.
Spatial expression patterns of tulip1 during zebraﬁsh
embryonic development
To determine the spatial expression pattern of tulip1 in zebraﬁsh,
whole-mount in situ hybridization of tulip1 mRNA was performed. At
the two-cell stage, tulip1 mRNA was distributed throughout the two
blastomeres (Fig. 4A), indicating that this mRNA was deposited
maternally. At the shield stage, after the launch of zygotic gene
expression, tulip1mRNA was expressed equally in whole blastomeres
(Fig. 4B) and this ubiquitous expression pattern was retained during
gastrulation and continued until the middle of the segmentation
period (Figs. 4C and D). Later in development, distribution of tulip1
mRNA shifted anteriorly and was restricted to the head region of
embryos (Figs. 4E–G), suggesting a role for tulip1 in zebraﬁsh head
development.
Fig. 4. Expression and functional analyses of tulip1 in zebraﬁsh. (A–G) In situ hybridization of tulip1 mRNA during development. At the two-cell stage, tulip1 mRNA was deposited
maternally (A) and expressed ubiquitously until the middle of the segmentation period (B, shield stage; C, bud stage; D, 18 somite stage). Distribution of tulip1 mRNA was shifted
anteriorly and restricted in head region of embryos (E, 24 h post-fertilization (hpf); F, 48 hpf; G, 72 hpf). (J, O, P) Knockdown of tulip1 caused developmental delay of the head and
brain. Live whole embryos (H–J) and head cross sections corresponding to the midbrain (K, M, O) and hindbrain (L, N, P) of wild type (H, K, L), control MO-injected (I, M, N) and
tulip1 MO-injected (J, O, P) embryos at 72 hpf. Dorsal is at the top (E–P) and rostral is to the left (E–J).
417K. Shimojima et al. / Genomics 94 (2009) 414–422Gene knockdown of tulip1 causes severe developmental retardation of
the brain
To investigate whether tulip1 is involved in brain development, we
performed gene knockdown of tulip1 in zebraﬁsh using morpholino
antisense oligos (MO). At 72 h post-fertilization (hpf), tulip1 MO1-
injected embryos (Fig. 4J) exhibited hypomorphic heads compared to
wild type or control MO-injected embryos (Figs. 4H–I), whereas trunk
development was relatively normal. In addition, approximately half of
all morphants had an enlarged pericardium and increased yolk
extension thickness (see representative morphant; Fig. 4J). To
investigate whether these defects were caused by the gene-speciﬁc
knockdown of tulip1 or not, tulip1MO2, which is another morpholino
antisense oligo and non-overlapping with tulip1 MO1, was used.
Microinjection of tulip1 MO2 did not give rise to an enlarged
pericardium and rarely caused thickening of the yolk sac (data not
shown). Therefore, the heart and the yolk defects are not speciﬁc to
tulip1 knockdown. In contrast, tulip1MO1 andMO2 caused equivalent
growth retardation of the head suggesting that this defect was caused
by the speciﬁc knockdown of tulip1 (Figs. 5A and B).
Because the externally hypomorphic head in the zebraﬁsh
morphants was similar to the abnormality of the brain observed in
P1, serial sections of the head were prepared from tulip1MO–injected
zebraﬁsh embryos to examine speciﬁc brain morphology aberrations.
In the normal zebraﬁsh midbrain, the brain ventricle was positioned
on the section that crossed the middle of the eyes at 48 hpf (Fig. 5C).
This ventricle was obstructed around 60 hpf (Fig. 5E) and completely
buried until 72 hpf in wild type (Fig. 4K) and control MO-injected (Fig.
4M) zebraﬁsh. In the normal zebraﬁsh hindbrain, the rhombic lip at
48 hpf was thin and the groove of the medulla oblongata was opened
wide (Fig. 5D). The rhombic lip thickenedwith progressive embryonicdevelopment and, as a result, the groove of themedulla oblongatawas
almost fully occluded at 72 hpf in wild type (Fig. 4L) and control MO-
injected (Fig. 4N) zebraﬁsh. In contrast, in tulip1 MO-injected
embryos, the brain ventricle in the midbrain at 72 hpf was
unobstructed (Fig. 4O). Similarly, a thin rhombic lip and widely
opened groove of the medulla oblongata was observed in the
hindbrain at 72 hpf (Fig. 4P). These results indicated that the
development of the brain in tulip1 MO-injected embryos at
72 hpf (Fig. 4O, and P) corresponded to that of the wild type
embryo at 48–60 hpf (Figs. 5C–F), and suggested that tulip1
knockdown results in brain developmental delay by ≥12 h (also
compare Figs. 5C–D vs. H–I and compare Figs. 4K–L vs. Figs. 5J–K).
Whole-body developmental delay was less severe than brain
developmental delay; tulip1 MO-injected embryos at 72 hpf were
clearly as progressed as wild type embryos at 60 hpf (Fig. 5G).
Collectively, these results indicated that gene knockdown of tulip1
caused severe and speciﬁc brain developmental delay.
Discussion
Using aCGH, we identiﬁed a previously uncharacterized chromo-
somal deletion of 14q13.1q13.3 in a female patient with develop-
mental delay and intractable epilepsy. Familial analysis indicated that
the deletion occurred de novo. In the literature, there are at least 19
reported cases with deletions near 14q13, and the deletion identiﬁed
in the present patient (P1) is the smallest among them (Fig. 6) [6–13].
Clinical ﬁndings of available 10 of these previously reported cases are
summarized in Table 1. The common manifestations of the 14q13.2
deletion are developmental delay and mild microcephaly (Table 1). In
the 2.2-Mb deletion in P1, 15 genes are included according to the 2006
build (Fig. 1).
Fig. 5. tulip1 knockdown analyses of zebraﬁsh. Zebraﬁsh embryos at 48 hpf injected by tulip1MO1 (A) and MO2 (B) showed similar hypomorphic head. Cross section of the brain of
wild type (C–F) and tulip1MO1 embryo (H–K); midbrain (C, E, H, J) and hindbrain (D, F, I, K). Wild type embryos at 48 hpf (C, D) correspond to tulip1MO1 embryos at 60 hpf (H, I),
and wild type embryos at 60 hpf (E, F) correspond to tulip1 MO1 embryos at 84 hpf (J, K), which indicate developmental delay. (G) Wild type embryo at 60 hpf.
418 K. Shimojima et al. / Genomics 94 (2009) 414–422Schwarzbraun et al. considered TULIP1 as the candidate gene for
the neurological phenotypes of deletion 14q13, and analyzed the
genomic structure and the function [3]. According to the study, TULIP1
was expressed ubiquitously in pre- and postnatal human tissues. The
nucleotide sequence of TULIP1 was predicted to encode Rap–GapFig. 6. Chromosome 14 schematic (upper) with the each size of deletions from previously re
regions, respectively. Numbers included in parentheses indicate patient number in the re
holoprosencephaly.domains [3], which is also contained in TSC2, one of the genes
responsible for tuberous sclerosis. Since haploinsufﬁciency of TSC2
can affects neurological functions [3], Schwarzbraun et al. analyzed
the sequence of TULIP1 in a family with idiopathic basal ganglia
calciﬁcation (IBGC; Fahr disease), but found no association betweenported patients and P1. Black and gray bars indicate conﬁrmed and suspected deletion
ference manuscripts. Asterisks indicate results derived from the same patient. HPE:
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420 K. Shimojima et al. / Genomics 94 (2009) 414–422TULIP1 mutation and idiopathic basal ganglia calciﬁcation. Whereas,
the similarities between TULIP1 and TSC2 led us to hypothesize that
TULIP1 might be associated with the idiopathic developmental delay
and epilepsy.
In the present study, reduced TULIP1 levels were observed in cell
lysates from immortalized lymphocytes derived from P1 (Fig. 3).
Subsequent mutation analyses identiﬁed no TULIP1 mutation on the
remaining allele. This evidence indicates that TULIP1 expression is
allele-dose dependent, making TULIP1 a credible candidate gene for
the phenotype of P1. We therefore analyzed the entire TULIP1 coding
region from 140 subjects with developmental delay and/or epilepsy.
From this second screening, four individual TULIP1 missense muta-
tions were identiﬁed in four patients (Supplementary Fig. 2), and two
of them were located within conserved sequence region among
mammalian species (Supplementary Fig. 4). However, all four
missense mutations were inherited from their healthy parents
(Supplementary Figs. 2 and 3).
To conﬁrm whether TULIP1 deletion inﬂuenced the phenotypic
appearance of P1, we used a zebraﬁsh knockdown system in which
expression of the zebraﬁsh homolog of TULIP1 was artiﬁcially
depressed. We ﬁrst identiﬁed and sequenced the full-length cDNA
of zebraﬁsh tulip1 including the 5′ and 3′ UTRs; the zebraﬁsh and
human sequences shared 72% identity. In situ hybridization revealed
that Tulip1 was expressed in the wild type zebraﬁsh forebrain and
tulip1 knockdown resulted in brain developmental delay but normal
whole body development. These ﬁndings are comparable to that
observed for P1, who had TULIP1 deletion and manifested severe
developmental delay, intractable epilepsy, and mild cerebral atrophy.
Kamnasaran et al. reported six patients associated with holopro-
sencephaly and common 14q13 microdeletion, which is overlapped
with that of the present patient (P1) (Fig. 6) [14]. In spite of common
deletions, penetrance of holoprosencephaly was not 100%, which
may depend on the parental origin of the deletion. Uniparental
disomy of chromosome 14 (UPD14) results in a distinctive
phenotype with developmental delay and dysmorphic features
depending on the parental origin [15,16]. Although the imprinting
locus of UPD14 is far from the 14q13 locus, we cannot deny the
possibility that penetrance of holoprosencephaly is inﬂuenced by the
allele origin.
As same as this manner, TULIP1 may be inﬂuenced by genomic
imprinting. Although the missense mutation P297T was shared with
P2 and her healthy father, western blotting analyses showed reduced
TULIP1 expression in immortalized lymphocyte cell extracts from P2.
If TULIP1was transcribed only from the paternal allele, P2 would only
be able to synthesize the mutated protein [17]. The evidence that
chromosomal deletion of 14q13.q13.3 in P1 was derived from
paternal allele may support this hypothesis. Therefore, we cannot
rule out possible pathogenicity of familial missense mutations
identiﬁed in this study.
Materials and methods
Materials
After informed consent based on the permission of the ethical
committee of Tokyo Women's Medical University, peripheral blood
samples of 300 patients with idiopathic mental retardation and/or
epilepsy of unidentiﬁed etiology were accumulated to investigate
potential genomic copy number aberrations using aCGH. In some
cases of chromosomal aberrations, blood samples were also obtained
from both parents of the patient. The samples in which no genomic
copy number aberrations were identiﬁed were used in the second
screening to identify whether gene-speciﬁc mutations were present.
In this study, 40 samples derived from patients with neurological
symptoms including developmental delay and/or epilepsy were used
for the second screening. An additional 100 subjects, which weredetermined by aCGH to be negative for chromosomal aberrations and
other known disease-causing mutations, including mutation of FMR1,
AFF2, PQBP1, ARX, MECP2, ATRX, RPS6KA3, IL1RAPL1, TSPAN7, OPHN1,
PAK3, ACSL4, AGTH2, ARHGEF6, GDI1, SLC6A8, FTSJ1, ZNF41, and DLG3,
were provided by the consortium of Research Resource for Mental
Retardation supported by the Ministry of Welfare, Labor, and Health
of Japan [18]. One hundred DNA samples from peripheral blood
lymphocyte of healthy Japanese volunteers and one hundred
Caucasian DNA samples (Caucasian Panel of 100 (HD100CAU); Coriell
Institute for Medical Research, USA) were also used for the population
study.
aCGH analysis
Genomic DNA was extracted from peripheral blood using the QIA
quick DNA extraction kit (Qiagen, Hilden, Germany). Genomic copy
number aberrations were analyzed using the Human Genome CGH
Microarray 105A chip (Agilent Technologies, Santa Clara, CA)
according to the method described elsewhere [19–22]. Brieﬂy,
500 ng patient and reference DNA from healthy Japanese individuals
were digested with restriction enzymes, Alu I and RsaI (Promega,
Madison, WI). Cy-5 (patient) or Cy-3 dUTP (reference) were
incorporated using Klenow fragment. The array was hybridized with
labeled patient and reference DNA in the presence of Cot-1 DNA
(Invitrogen, Carlsbad, CA) and blocking agents (Agilent Technologies)
for 40 h at 65 °C, washed and scanned on the scanner (Agilent
Technologies). Data was extracted using Agilent Feature Extraction
software ver 9 with the default settings for aCGH analysis. Statistically
signiﬁcant aberrations were determined using the ADM-II algorithm
in CGH Analytics software version 3.5 (Agilent Technologies). Break-
points were deﬁned as the start and stop location of the ﬁrst and last
probes, respectively, included in the algorithmically determined
region of deletion.
Fluorescence in situ hybridization (FISH) analysis
Metaphase or prometaphase chromosomes were prepared from
phytohemagglutinin-stimulated peripheral blood lymphocytes
according to standard techniques. Four bacterial artiﬁcial chromosome
(BAC) clones RP11-557O15 (14q13.1; 32,770,543//32,934,772),
RP11-26M6 (14q13.2; 34,404,823//34,591,592), RP11-35M15
(14q13.2; 35,104,496//35,263,440) and RP11-81F13 (14q13.3;
36,297,744//36,467,869) that mapped around 14p13.2 were selected
from the in-silico library build 2006 (UCSC Human genome browser,
March 2006, http://genome.ucsc.edu/) and were purchased from
Invitrogen (Germany). Clone RP11-112H5 (14q32.33; 105,798,044//
105,952,495) was used for the marker of chromosome 14.
FISH analyses were performed using a combination of two BAC
clones with the target clone and the marker clone [22]. Brieﬂy, slide-
mounted chromosomes were hardened at 65 °C for 150 min and then
denatured in 70% formamide containing 2× standard saline citrate
(SSC) at 70 °C for 2 min, and then dehydrated at −20 °C in ethanol.
1.5 μg of BAC clone DNA extracted using GenePrepStar PI-80X
(Kurabo, Osaka, Japan) was labeled with SpectrumGreen TM-11-
dUTP or SpectrumOrange TM-11-dUTP (Vysis, Downers Grove, IL) via
nick translation and denatured at 70 °C for 5 min in the probe
hybridization mixture including 50% of formamide, 2×SSC, and 10%
dextran sulfate. Then, it was applied on the chromosomes, and
incubated at 37 °C for 16 h. Slides were washed twice in 50%
formamide containing 2×SSC at 43 °C for 15 min, 2×SSC for 5 min,
1×SSC for 5 min, 0.1% (v/v) Triton X-100/4×SSC for 5 min with
shaking, 4×SSC for 5 min, then 2×SSC for 5 min and then mounted in
antifade solution (Vector, Burlingame, CA) containing 4′,6-diamino-2-
phenylindole (DAPI). Photomicroscopy was performed under a
microscope equipped with a quad ﬁlter set containing single band
excitation ﬁlters (Leica Microsystems, Tokyo, Japan).
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Familial relationships and the origin of the 14q13.1q13.3 deletion
for P1 were analyzed using the PRISM Linkage Mapping Set Panel 20
(Applied Biosystems Inc, Foster City, CA), which includes the primer
sets of 14 microsatellite markers D14S261, D14S283, D14S275,
D14S70, D14S288, D14S276, D14S63, D14S258, D14S74, D14S68,
D14S280, D14S65, D14S985 and D14S292. PCR ampliﬁcation using
True Allele PCR Premix (Applied Biosystems Inc.) was performed
according to the manufacture's protocol [23]. Then, the products were
separated using the 3130xl Genetic Analyzer (Applied Biosystems Inc.)
and analyzed by GeneMapper software (Applied Biosystems Inc.).
Mutation screening of the TULIP1 coding region
All 41 TULIP1 exons from each patient were ampliﬁed by PCR
using originally designed primers located on the both neighboring
intronic sequences (Supplementary Table 2) according to the
standard method. All amplicons were subjected to direct sequencing
using the BigDye Terminator Cycle Sequencing kit (Applied Biosys-
tems Inc.) according to the manufacturer's protocol. Sequencing
reactions were separated using a 3130xl Genetic Analyzer (Applied
Biosystems Inc.).
Because exon 33 was too large to analyze in the samemanner with
the other exons, it was divided into several parts. However, primers
based on the exonic sequence could not be used for PCR due to the
existence of the pseudogene of TULIP1 which had quite similar
sequences. When we use the primers on the coding region of exon 33
for PCR ampliﬁcation, both the true TULP1 and pseudo TULIP1 were
ampliﬁed. To circumvent this difﬁculty, the entire exon 33 was PCR
ampliﬁed by both neighboring intron-based primers, which cannot
amplify exon 33 of the pseudogene of TULIP1, and used as a template
for direct sequencing using sequential exon-based primers.
Western blotting
Immortalized lymphocytes were collected by centrifugation at
1400×g and homogenized in sample buffer (50 mM Tris–HCl, pH 6.8,
2% sodium dodecyl sulfate (SDS), and 10% (v/v) glycerol) by
sonication. β-Mercaptoethanol and bromophenol blue were added
to cell lysates at ﬁnal concentrations of 6% (v/v) and 0.003%,
respectively. Proteins were resolved by SDS-PAGE and transferred to
polyvinylidene diﬂuoride membranes (Immobilon; Millipore, Bill-
erica, MA). Membranes were blocked in phosphate buffered saline
(PBS) containing 10% nonfat milk and 0.05% (w/v) Tween 20 for 1 h at
room temperature. Membranes were then incubated with rabbit
polyclonal anti-GARNL1 (TULIP1) (1:100 dilution, HPA00851; Atlas
Antibodies, Sweden) or anti-β-actin monoclonal antibody (1:5000
dilution, A5441; Sigma, MO) overnight at 4 °C. Membranes were
washed three times in PBS containing 0.05% Tween 20 and then
incubated in HRP-conjugated secondary antibody for 1 h at 37 °C.
Membranes were washed as before and signals were detected using
SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher
Scientiﬁc Inc., Rockford, IL) and FUJI RAS3000 (FUJI Film, Tokyo,
Japan).
Zebraﬁsh maintenance
Adult zebraﬁsh (Danio rerio) were maintained at 28.5 °C under
14 h light/10 h dark cycle conditions. Embryos from natural crosses
were collected a fewminutes after spawning and cultured at 28.5 °C in
water containing 0.006% NaCl and 0.00025%methylene blue. Embryos
were staged according to morphology and hours post-fertilization
(hpf) as described [4]. For in situ hybridization, N-phenylthiourea was
added to culture water at a ﬁnal concentration of 0.003% to avoid
pigmentation of larvae.Cloning of zebraﬁsh tulip1
The sequence of the zebraﬁsh tulip1 cDNA has been previously
predicted using genomic data (GenBank accession XM_679242). In this
study, the cDNA corresponding to theopen reading frame(ORF) of tulip1
was cloned by reverse transcription-polymerase chain reaction (RT-
PCR) using primers designed based on the predicted sequence. Brieﬂy,
total RNAwas extracted from14 somite stage embryos using theRNeasy
Mini Kit (Qiagen), and cDNA was synthesized using the Omniscript RT
Kit (Qiagen) according to the manufacturer's instructions. All PCR
ampliﬁcation reactions were performed using KOD plus DNA polymer-
ase (TOYOBO,Osaka, Japan). The5′ and3′untranslated regionswere also
clonedby the rapid ampliﬁcationof cDNAends (RACE)methodusing the
5′-RACE Core Set (TAKARA, Otsu, Japan). (The sequences of the primers
used in this study are shown in Supplementary Table 3.)
Whole mount in situ hybridization of tulip1 RNA
Whole-mount in situ hybridization was performed as described [4].
Brieﬂy, digoxigenin-labeled antisense RNA probes, complementary to
four partially overlapping regions of zebraﬁsh tulip1, were synthesized.
These probes corresponded to the following regions of tulip1; nt 511–
1526, nt 1303–2337, nt 3714–4733 or nt 4527–5644 (relative the
transcriptional start site GenBank accession AB476643 and AB476644).
Because these four probes displayed identical staining patterns, they
were used as amixture. To enhance the contrast of the signal of tulip1 in
shield and bud stage embryos, specimens were soaked in transparency
reagent (2:1 mixture of benzyl benzonate/benzyl alcohol).
Morpholino oligos and microinjection
Morpholino antisense oligos (MOs) were purchased from Gene
Tools, LLC. The sequences of the two non-overlapping MOs used in
this study were as follows: tulip1 MO1, 5′-GAGATGTTTTGAAGAGC-
TAATGATA-3′; tulip1 MO2, 5′-TCTTCCGTTAATTCCCTCAAACATG-3′.
We also used the following control MO that does not match any
zebraﬁsh gene: 5′-AAACGTCTCTTGACTCTCCGCGATG-3′. MOs were
dissolved in Danieau solution (5 mM HEPES, pH 7.6, 58 mM NaCl,
0.7 mM KCl, 0.4 mM MgSO4, and 0.6 mM Ca(NO3)2) to a ﬁnal
concentration of at 10 μg/μl and stored at −20 °C. MOs were
microinjected at 3 ng/nl as described [4].
Preparation of zebraﬁsh head sections
Zebraﬁsh embryos in appropriate stages were ﬁxed in PBS
containing 4% paraformaldehyde (PFA) at 4 °C overnight. The ﬁxed
embryos were gradually dehydrated with ethanol and then com-
pletely dehydrated using 2-propanol. Dehydrated embryos were
soaked in xylene and embedded following transfer to Paraplast Plus
embedding medium (McCormick Scientiﬁc, St. Louis, MO) under
microscopic observation. Specimens were cut into serial sections
(7 μm) and stained using Mayer's hematoxylin and eosin solutions.
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